Published in Proteomics on September 01, 2003
Characterising phase variations in MALDI-TOF data and correcting them by peak alignment. Cancer Inform (2005) 0.95
Parametric power spectral density analysis of noise from instrumentation in MALDI TOF mass spectrometry. Cancer Inform (2007) 0.88
Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology (2005) 9.83
The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol (2007) 2.93
Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol (2012) 2.72
Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA (2010) 2.68
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer (2009) 2.06
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. J Thorac Oncol (2015) 2.02
Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer (2006) 1.91
Order out of disorder: working cycle of an intrinsically unfolded chaperone. Cell (2012) 1.89
Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol (2007) 1.86
Structural and thermodynamic characterization of a cytoplasmic dynein light chain-intermediate chain complex. Proc Natl Acad Sci U S A (2007) 1.71
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56
Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol (2008) 1.38
Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res (2003) 1.34
Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007. Radiology (2013) 1.30
Thermodynamic analysis of protein stability and ligand binding using a chemical modification- and mass spectrometry-based strategy. Anal Chem (2008) 1.27
Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics (2003) 1.27
Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project. J Natl Cancer Inst (2006) 1.24
The protein backbone makes important contributions to 4-oxalocrotonate tautomerase enzyme catalysis: understanding from theory and experiment. Biochemistry (2004) 1.23
Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer (2004) 1.16
Quantitative proteomics approach for identifying protein-drug interactions in complex mixtures using protein stability measurements. Proc Natl Acad Sci U S A (2010) 1.14
A general mass spectrometry-based assay for the quantitation of protein-ligand binding interactions in solution. J Am Chem Soc (2002) 1.12
Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer (2007) 1.11
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer (2004) 1.10
Mutational analysis of active site residues in the Staphylococcus aureus transpeptidase SrtA. Biochemistry (2007) 1.07
Accuracy and precision of a new H/D exchange- and mass spectrometry-based technique for measuring the thermodynamic properties of protein-peptide complexes. Biochemistry (2003) 1.07
In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:glyoxylate aminotransferase. J Biol Chem (2008) 1.06
Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res (2005) 1.03
The SID-1 double-stranded RNA transporter is not selective for dsRNA length. RNA (2009) 1.02
Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer (2004) 1.01
False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. AJR Am J Roentgenol (2004) 1.00
A new H/D exchange- and mass spectrometry-based method for thermodynamic analysis of protein-DNA interactions. Chem Biol (2003) 1.00
PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer (2002) 0.97
SUPREX (Stability of Unpurified Proteins from Rates of H/D Exchange) analysis of the thermodynamics of synergistic anion binding by ferric-binding protein (FbpA), a bacterial transferrin. Biochemistry (2004) 0.97
H/D exchange- and mass spectrometry-based strategy for the thermodynamic analysis of protein-ligand binding. Anal Chem (2007) 0.97
Accuracy of SUPREX (stability of unpurified proteins from rates of H/D exchange) and MALDI mass spectrometry-derived protein unfolding free energies determined under non-EX2 exchange conditions. J Am Soc Mass Spectrom (2006) 0.97
High-throughput screening assay for the tunable selection of protein ligands. J Comb Chem (2004) 0.96
Characterising phase variations in MALDI-TOF data and correcting them by peak alignment. Cancer Inform (2005) 0.95
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology (2002) 0.95
Theoretical and experimental determination on two substrates turned over by 4-oxalocrotonate tautomerase. J Phys Chem A (2006) 0.94
Slow histidine H/D exchange protocol for thermodynamic analysis of protein folding and stability using mass spectrometry. Anal Chem (2012) 0.93
Analysis of protein folding and function using backbone modified proteins. Bioorg Chem (2004) 0.93
Thermodynamic analysis of protein-ligand interactions in complex biological mixtures using a shotgun proteomics approach. J Proteome Res (2011) 0.93
The role of imaging in malignant pleural mesothelioma. Semin Oncol (2002) 0.93
Hijacking transferrin bound iron: protein-receptor interactions involved in iron transport in N. gonorrhoeae. Metallomics (2009) 0.92
Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate. Anal Chem (2004) 0.91
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol (2006) 0.91
Practical approach to diagnostic CT combined with PET. AJR Am J Roentgenol (2007) 0.89
Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertil Steril (2013) 0.89
Thermodynamic stability measurements on multimeric proteins using a new H/D exchange- and matrix-assisted laser desorption/ionization (MALDI) mass spectrometry-based method. Protein Sci (2002) 0.89
LPS and poly I:C induce chromatin modifications at a novel upstream region of the IL-23 p19 promoter. Inflammation (2008) 0.89
H/D exchange and mass spectrometry-based method for biophysical analysis of multidomain proteins at the domain level. Anal Chem (2007) 0.89
Biomarkers to help guide management of patients with pulmonary nodules. Am J Respir Crit Care Med (2013) 0.89
Ex vivo analysis of synergistic anion binding to FbpA in Gram-negative bacteria. Biochemistry (2008) 0.88
Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. Cancer (2010) 0.88
Thermodynamic analysis of protein-ligand binding interactions in complex biological mixtures using the stability of proteins from rates of oxidation. Nat Protoc (2012) 0.87
Thermodynamic analysis of subunit interactions in Escherichia coli molybdopterin synthase. Biochemistry (2005) 0.86
Conserved thermodynamic contributions of backbone hydrogen bonds in a protein fold. Proc Natl Acad Sci U S A (2006) 0.86
Stable isotope labeling strategy for protein-ligand binding analysis in multi-component protein mixtures. J Am Soc Mass Spectrom (2011) 0.86
Mass spectrometry-based thermal shift assay for protein-ligand binding analysis. Anal Chem (2010) 0.86
Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res (2010) 0.84
Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005. J Thorac Oncol (2014) 0.84
Thermodynamic analysis of a molecular chaperone binding to unfolded protein substrates. Biochemistry (2010) 0.83
Thermodynamic analysis of protein folding and stability using a tryptophan modification protocol. Anal Chem (2014) 0.83
Leucine-rich repeat (in Flightless I) interacting protein-1 regulates a rapid type I interferon response. J Interferon Cytokine Res (2010) 0.83
Total synthesis, assignment of the absolute stereochemistry, and structure-activity relationship studies of subglutinols A and B. Chem Asian J (2010) 0.82
Mass spectrometry- and lysine amidination-based protocol for thermodynamic analysis of protein folding and ligand binding interactions. Anal Chem (2011) 0.82
Facile chemical synthesis and equilibrium unfolding properties of CopG. Protein Sci (2004) 0.82
Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection. J Am Soc Mass Spectrom (2008) 0.81
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. J Thorac Oncol (2007) 0.81
Finding diagnostic biomarkers in proteomic spectra. Pac Symp Biocomput (2006) 0.80
Comparative analysis of two different amide-to-ester bond mutations in the beta-sheet of 4-oxalocrotonate tautomerase. Biochemistry (2003) 0.80
SILAC-pulse proteolysis: A mass spectrometry-based method for discovery and cross-validation in proteome-wide studies of ligand binding. J Am Soc Mass Spectrom (2014) 0.80
The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. J Thorac Oncol (2011) 0.79
Direct analysis of backbone-backbone hydrogen bond formation in protein folding transition states. J Mol Biol (2006) 0.79
Ga3+ as a mechanistic probe in Fe3+ transport: characterization of Ga3+ interaction with FbpA. J Biol Inorg Chem (2008) 0.79
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer (2011) 0.78
False-positive rate determination of protein target discovery using a covalent modification- and mass spectrometry-based proteomics platform. J Am Soc Mass Spectrom (2013) 0.78
Evidence of Fe3+ interaction with the plug domain of the outer membrane transferrin receptor protein of Neisseria gonorrhoeae: implications for Fe transport. Metallomics (2012) 0.78
Isolation of novel EGFR-specific VHH domains. J Biomol Screen (2009) 0.78